Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection
ConditionChronic Subdural Hematoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe Cooper Health System
About this trial
The goal of this clinical trial is to test whether infusing bevacizumab into the middle meningeal arteries can be used to treat chronic subdural hematomas (cSDH).
The main questions it aims to answer are:
* Is bevacizumab infusion safe in cSDH patients? * Is bevacizumab infusion effective in treating cSDH?
Eligibility criteria
Qualifiers
Adult patients (≥18 years)
Radiographic evidence of chronic subdural hematoma, including
Persistence of subdural blood more than 10 days after index traumatic injury or event
Presence of mixed density blood
Disqualifiers
Pregnant, breastfeeding, or unwilling to practice contraception during participation in the study.
Patients with concomitant intracranial pathology other than subdural hematoma (e.g., intracranial malignancy).
Patients with known hypersensitivity to bevacizumab.
Patients with radiographic evidence of mass effect.
Trial design
Treatments tested in this trial
- Bevacizumab 2 mg/kg
- Bevacizumab 4 mg/kg
Treatment groups
140 Participants
are divided into 4 treatment groupsSponsors and collaborators
The Cooper Health System
Lead sponsor
Society of Vascular and Interventional Neurology
Collaborator
Source ClinicalTrials.gov